188 related articles for article (PubMed ID: 19882093)
1. Potentials of curcumin as an antidepressant.
Kulkarni S; Dhir A; Akula KK
ScientificWorldJournal; 2009 Nov; 9():1233-41. PubMed ID: 19882093
[TBL] [Abstract][Full Text] [Related]
2. Combination therapy with monoamine oxidase inhibitors and other antidepressants or stimulants: strategies for the management of treatment-resistant depression.
Thomas SJ; Shin M; McInnis MG; Bostwick JR
Pharmacotherapy; 2015 Apr; 35(4):433-49. PubMed ID: 25884531
[TBL] [Abstract][Full Text] [Related]
3. Further evaluation of the neuropharmacological determinants of the antidepressant-like effects of curcumin.
Witkin JM; Leucke S; Thompson LK; Lynch RA; Ding C; Heinz B; Catlow JT; Gleason SD; Li X
CNS Neurol Disord Drug Targets; 2013 Jun; 12(4):498-505. PubMed ID: 23574162
[TBL] [Abstract][Full Text] [Related]
4. Curcumin as a putative antidepressant.
Seo HJ; Wang SM; Han C; Lee SJ; Patkar AA; Masand PS; Pae CU
Expert Rev Neurother; 2015 Mar; 15(3):269-80. PubMed ID: 25644944
[TBL] [Abstract][Full Text] [Related]
5. Antidepressant effects of curcumin and HU-211 coencapsulated solid lipid nanoparticles against corticosterone-induced cellular and animal models of major depression.
He X; Zhu Y; Wang M; Jing G; Zhu R; Wang S
Int J Nanomedicine; 2016; 11():4975-4990. PubMed ID: 27757031
[TBL] [Abstract][Full Text] [Related]
6. [Antidepressive agents in the elderly].
de Hooge JK
Tijdschr Gerontol Geriatr; 1990 Dec; 21(6):259-67. PubMed ID: 1980385
[TBL] [Abstract][Full Text] [Related]
7. The putative antidepressant DOV 216,303, a triple reuptake inhibitor, increases monoamine release in the prefrontal cortex of olfactory bulbectomized rats.
Prins J; Denys DA; Westphal KG; Korte-Bouws GA; Quinton MS; Schreiber R; Groenink L; Olivier B; Korte SM
Eur J Pharmacol; 2010 May; 633(1-3):55-61. PubMed ID: 20153745
[TBL] [Abstract][Full Text] [Related]
8. Multiple antidepressant potential modes of action of curcumin: a review of its anti-inflammatory, monoaminergic, antioxidant, immune-modulating and neuroprotective effects.
Lopresti AL; Hood SD; Drummond PD
J Psychopharmacol; 2012 Dec; 26(12):1512-24. PubMed ID: 23035031
[TBL] [Abstract][Full Text] [Related]
9. Monoamine neurocircuitry in depression and strategies for new treatments.
Hamon M; Blier P
Prog Neuropsychopharmacol Biol Psychiatry; 2013 Aug; 45():54-63. PubMed ID: 23602950
[TBL] [Abstract][Full Text] [Related]
10. Curcumin in antidepressant treatments: An overview of potential mechanisms, pre-clinical/clinical trials and ongoing challenges.
Zhang Y; Li L; Zhang J
Basic Clin Pharmacol Toxicol; 2020 Oct; 127(4):243-253. PubMed ID: 32544307
[TBL] [Abstract][Full Text] [Related]
11. Current investigational drugs for major depression.
Kulkarni SK; Dhir A
Expert Opin Investig Drugs; 2009 Jun; 18(6):767-88. PubMed ID: 19426122
[TBL] [Abstract][Full Text] [Related]
12. Antidepressant-like effects of water extract of Gastrodia elata Blume in rats exposed to unpredictable chronic mild stress via modulation of monoamine regulatory pathways.
Lin YE; Lin SH; Chen WC; Ho CT; Lai YS; Panyod S; Sheen LY
J Ethnopharmacol; 2016 Jul; 187():57-65. PubMed ID: 27109341
[TBL] [Abstract][Full Text] [Related]
13. Antidepressant effects of curcumin in the forced swim test and olfactory bulbectomy models of depression in rats.
Xu Y; Ku BS; Yao HY; Lin YH; Ma X; Zhang YH; Li XJ
Pharmacol Biochem Behav; 2005 Sep; 82(1):200-6. PubMed ID: 16171853
[TBL] [Abstract][Full Text] [Related]
14. Reversible monoamine oxidase-A inhibitors in resistant major depression.
Nolen WA; Hoencamp E; Bouvy PF; Haffmans PM
Clin Neuropharmacol; 1993; 16 Suppl 2():S69-76. PubMed ID: 8313400
[TBL] [Abstract][Full Text] [Related]
15. Remarkable effect of selegiline (L-deprenyl), a selective monoamine oxidase type-B inhibitor, in a patient with severe refractory depression: a case report.
Higuchi H; Kamata M; Sugawara Y; Yoshida K
Clin Neuropharmacol; 2005; 28(4):191-2. PubMed ID: 16062100
[TBL] [Abstract][Full Text] [Related]
16. The monoaminergic tripartite synapse: a putative target for currently available antidepressant drugs.
Quesseveur G; Gardier AM; Guiard BP
Curr Drug Targets; 2013 Oct; 14(11):1277-94. PubMed ID: 24020973
[TBL] [Abstract][Full Text] [Related]
17. Triple reuptake inhibitors for treating subtypes of major depressive disorder: the monoamine hypothesis revisited.
Prins J; Olivier B; Korte SM
Expert Opin Investig Drugs; 2011 Aug; 20(8):1107-30. PubMed ID: 21682663
[TBL] [Abstract][Full Text] [Related]
18. Add-on Treatment with Curcumin Has Antidepressive Effects in Thai Patients with Major Depression: Results of a Randomized Double-Blind Placebo-Controlled Study.
Kanchanatawan B; Tangwongchai S; Sughondhabhirom A; Suppapitiporn S; Hemrunrojn S; Carvalho AF; Maes M
Neurotox Res; 2018 Apr; 33(3):621-633. PubMed ID: 29327213
[TBL] [Abstract][Full Text] [Related]
19. Pharmacotherapy of depression: a historical analysis.
Ban TA
J Neural Transm (Vienna); 2001; 108(6):707-16. PubMed ID: 11478422
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of antidepressant-like activity of novel water-soluble curcumin formulations and St. John's wort in behavioral paradigms of despair.
Kulkarni SK; Akula KK; Deshpande J
Pharmacology; 2012; 89(1-2):83-90. PubMed ID: 22343362
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
